About: Convalescent plasma transfusion for the treatment of COVID‐19: Systematic review

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Convalescent plasma transfusion for the treatment of COVID‐19: Systematic review Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Convalescent plasma transfusion for the treatment of COVID‐19: Systematic review
Creator	Prof, Associate Dir, Prof Krishnasamy, Narayanasamy Natarajan, Murugan Rajendran, Karthick Ramachandran, Arunkumar Rangarajan, Jayanthi Scientist, Research
Source	Medline; PMC
abstract	The recent emergence of coronavirus disease 2019 (COVID‐19) pandemic has reassessed the usefulness of historic convalescent plasma transfusion (CPT). This review was conducted to evaluate the effectiveness of CPT therapy in COVID‐19 patients based on the publications reported till date. To our knowledge, this is the first systematic review on convalescent plasma on clinically relevant outcomes in individuals with COVID‐19. PubMed, EMBASE, and Medline databases were searched upto 19 April 2020. All records were screened as per the protocol eligibility criteria. We included five studies reporting CPT to COVID‐19 patients. The main findings from available data are as follows: (a) Convalescent plasma may reduce mortality in critically ill patients, (b) Increase in neutralizing antibody titers and disappearance of SARS‐CoV‐2 RNA was observed in almost all the patients after CPT therapy, and (c) Beneficial effect on clinical symptoms after administration of convalescent plasma. Based on the limited scientific data, CPT therapy in COVID‐19 patients appears safe, clinically effective, and reduces mortality. Well‐designed large multicenter clinical trial studies should be conducted urgently to establish the efficacy of CPT to COVID‐19 patients.
has issue date	2020-05-12(xsd:dateTime)
bibo:doi	10.1002/jmv.25961
bibo:pmid	32356910
has license	no-cc
sha1sum (hex)	e5402d8e22d056071dc618a80789d7f9d5595aeb
schema:url	https://doi.org/10.1002/jmv.25961
resource representing a document's title	Convalescent plasma transfusion for the treatment of COVID‐19: Systematic review
has PubMed Central identifier	PMC7267113
has PubMed identifier	32356910
schema:publication	J Med Virol
resource representing a document's body	covid:e5402d8e22d056071dc618a80789d7f9d5595aeb#body_text
is schema:about of	named entity 'plasma' named entity 'plasma' named entity 'EMERGENCE' named entity 'COVID-19' named entity 'coronavirus disease 2019' named entity 'CPT' named entity 'COVID-19' named entity 'reduce symptoms' named entity 'infectious diseases' named entity 'blood drawn' named entity 'global health' named entity 'viral load' named entity 'Germany' named entity 'control groups' named entity 'IgG' named entity 'systematic reviews' named entity 'neutralizing antibodies' named entity 'COVID' named entity 'CPT' named entity 'CPT' named entity 'convalescent plasma transfusion' named entity 'China' named entity 'meta-analyses' named entity 'IgM' named entity 'drug screens' named entity 'neutralizing antibodies' named entity 'CPT' named entity 'antibody' named entity 'vaccines' named entity 'infectious diseases' named entity 'critical care' named entity 'transfusion' named entity 'CPT' named entity 'clinical outcome' named entity 'COVID-19 outbreak' named entity 'convalescent plasma' named entity 'Comorbidity' named entity 'clinical trials' named entity 'United States of America' named entity 'Study population' named entity 'adverse events' named entity 'CPT' named entity 'World Health Organization' named entity 'antibody titer' named entity 'spreadsheet' named entity 'PROSPERO' named entity 'Embase' named entity 'convalescent plasma' named entity 'PubMed' named entity 'viral load' named entity 'systematic review' named entity 'international registries' named entity 'animal models' named entity 'RCT' named entity 'high-quality' named entity 'CPT' named entity 'COVID' named entity 'COPD' named entity 'Italy' named entity 'epidemic' named entity 'clinical studies' named entity 'case reports' named entity 'case report' named entity 'Passive immunization' named entity 'supportive care' named entity 'scientific evidence' named entity 'preclinical trials' named entity 'clinical symptoms' named entity 'COVID' named entity 'critically ill' named entity 'Medline' named entity 'coronavirus' named entity 'data extraction' named entity 'United Kingdom'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software